Published online before print November 17, 2003, doi: 10.1161/01.CIR.0000103680.61390.16
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:2743.)
© 2003 American Heart Association, Inc.
Brief Rapid Communications |
Lipid Lowering by Pravastatin Increases Parasympathetic Modulation of Heart Rate
G
i2, a Possible Molecular Marker for Parasympathetic Responsiveness
From The Children’s Heart Program (C.M.W., J.P.S.), Medical University of South Carolina, Charleston, SC; Department of Internal Medicine (D.-G.S., Y.-J.K.), Yeungnam University Hospital, Daegu, Korea; and Molecular Cardiology Research Institute (H.-J.P., J.B.G.), Cardiovascular Division, Department of Medicine, Tufts-New England Medical Center and Tufts Medical School, Boston, Mass.
Correspondence to Jonas B. Galper, Tufts-New England Medical Center Box #8486, 750 Washington St, Boston, MA 02111. E-mail Jgalper{at}Tufts-NEMC.org
Received March 11, 2003; de novo received August 8, 2003; revision received October 2, 2003; accepted October 6, 2003.
Background— We have previously demonstrated in an in vitro model for lipid lowering that lipoprotein depletion resulted in a marked increase in the negative chronotropic response to the acetylcholine analogue carbamylcholine. In this study we used heart rate variability analysis to determine the effect of lipid lowering by statins on the response of the heart to parasympathetic stimulation. In parallel, we examined whether changes in parasympathetic responsiveness correlated with changes in the expression of Gi2, a molecular component of the parasympathetic signaling pathway in the heart.
Methods and Results— Patients were randomized in a crossover study of pravastatin and simvastatin. R-R interval analysis of Holter monitor studies demonstrated that in patients treated initially with pravastatin, the peak high-frequency power fraction during sleep, which reflects parasympathetic modulation of heart rate, increased by 24.0±5.02% (SEM, n=13, P<0.001) compared with the untreated control value. Simvastatin had no significant effect. Western blot analysis of lymphocytes from patients treated with pravastatin demonstrated a 90.1±27.3% (n=10, P=0.009) increase in Gi2 expression, whereas simvastatin had no effect. Relative changes in Gi2 correlated significantly with the changes in the fraction of high-frequency power (
=0.574, P=0.016).
Conclusions— Taken together with our in vitro data, these data are the first to suggest that cholesterol lowering by pravastatin might increase the response of the heart to parasympathetic stimulation and that changes in Gi2 expression might serve as a molecular marker for this effect.
Key Words: lipids • statins • heart rate
This article has been cited by other articles:
 |
|
 |
|
  H. H.H. Feringa, O. Schouten, S. E. Karagiannis, J. Brugts, A. Elhendy, E. Boersma, R. Vidakovic, M. R.H.M. van Sambeek, P. G. Noordzij, J. J. Bax, et al. Intensity of Statin Therapy in Relation to Myocardial Ischemia, Troponin T Release, and Clinical Cardiac Outcome in Patients Undergoing Major Vascular Surgery J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1649 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Mager and D. R. Abernethy Use of Wavelet and Fast Fourier Transforms in Pharmacodynamics J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 423 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schwartz, S. K. Park, M. S. O'Neill, P. S. Vokonas, D. Sparrow, S. Weiss, and K. Kelsey Glutathione-S-Transferase M1, Obesity, Statins, and Autonomic Effects of Particles: Gene-by-Drug-by-Environment Interaction Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1529 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Shishehbor, B. J. Hoogwerf, and M. S. Lauer Association of Triglyceride-to-HDL Cholesterol Ratio With Heart Rate Recovery Diabetes Care, April 1, 2004; 27(4): 936 - 941. [Abstract] [Full Text] [PDF]
|
|